Mazdutide For Lab Research

Product DescriptionBuy Mazdutide UK – >99% Purity | GLP-1R/GCGR Dual Agonist | Research Use OnlyMazdutide (IBI362 / LY3305677 / OXM3) is a synthetic oxyntomodulin-based dual agonist of the GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR) — currently in Phase 3 clinical development across five global trials and one of the most clinically advanced metabolic research peptides available today. Buy Mazdutide in the UK from Peptides Lab UK with >99% HPLC-verified purity, batch-specific COA, and fast UK dispatch for laboratory and in-vitro research use only.What is Mazdutide?Mazdutide (IBI362, also known by Eli Lilly’s development code LY3305677 and the pre-clinical identifier OXM3) is a synthetic peptide modelled on mammalian oxyntomodulin (OXM) — a naturally occurring gut hormone that itself acts as a dual GLP-1R/GCGR agonist. Developed by Innovent Biologics under an exclusive licence agreement with Eli Lilly and Company, Mazdutide is engineered to simultaneously activate both the GLP-1 receptor and the glucagon receptor with optimised affinity and balanced potency at each target.This dual receptor activation addresses two complementary components of metabolic disease simultaneously: GLP-1R agonism drives appetite suppression, gastric emptying delay, and glucose-dependent insulin secretion, while GCGR activation adds a distinct and meaningful increase in energy expenditure, hepatic fatty acid oxidation, and lipolysis — metabolic effects not achievable through GLP-1R agonism alone.Mazdutide is currently the most clinically advanced dual GLP-1R/GCGR agonist with completed Phase 3 data, and its NDA for chronic weight management is currently under review by China’s National Medical Products Administration (NMPA) — making it one of the most closely watched research peptides in the global metabolic disease community.Synonyms: IBI362, LY3305677, OXM3, Mazdutide Mechanism: GLP-1R and GCGR dual agonist (oxyntomodulin analog) Developer: Innovent Biologics / Eli Lilly (licensed) Purity: >99% (HPLC verified) Form: Lyophilised powder Storage: –20°C, protect from light and moistureHow Does Mazdutide Work?Mazdutide functions through two complementary receptor mechanisms that together produce a broader and more potent metabolic effect than either GLP-1 mono-agonism or glucagon mono-agonism alone:GLP-1 Receptor (GLP-1R) Activation:Suppresses appetite and reduces caloric intake through central hypothalamic satiety signallingSlows gastric emptying, prolonging postprandial satietyStimulates glucose-dependent insulin secretion from pancreatic beta cellsReduces post-meal blood glucose excursionsActivates cAMP/PKA and PI3K–Akt signalling pathways in multiple tissuesGlucagon Receptor (GCGR) Activation:Increases energy expenditure through hepatic and thermogenic pathways — the key differentiator from GLP-1 mono-agonistsPromotes hepatic fatty acid oxidation and lipolysis, directly reducing liver fat contentReduces hepatic lipid accumulation via direct glucagon-mediated pathways — confirmed to produce liver fat reductions exceeding those of GLP-1 mono-agonists and other dual agonistsLowers circulating uric acid levels via uricosuric mechanisms (confirmed across pre-clinical and clinical data)May uniquely counteract glutamate excitotoxicity — a neuroprotective pathway separate from those targeted by GLP-1 mono-agonistsThe synergy between these two pathways is the core of Mazdutide’s research rationale: GLP-1R reduces energy intake while GCGR increases energy expenditure, creating a dual-sided energy balance intervention that pre-clinical and clinical data suggest is more effective than either mechanism alone.What Does Mazdutide Do in Research?In pre-clinical models and Phase 1–3 clinical research, Mazdutide has demonstrated a broad range of significant metabolic effects:Bodyweight reduction — Phase 3 GLORY-1 trial (48 weeks, once-weekly subcutaneous dosing) demonstrated 14.8% bodyweight reduction at 6 mg versus 0.5% with placebo in Chinese adults with obesity or overweightSuperior liver fat reduction — exploratory MRI-PDFF analysis from GLORY-1 showed an 80.2% reduction in liver fat content versus baseline, exceeding results reported for GLP-1 mono-agonists and other dual-target agonists in comparable studiesHbA1c reduction — Phase 2 trials in Chinese adults with type 2 diabetes demonstrated significant HbA1c reduction, with full results published in Diabetes Care (2024)Multiple cardiometabolic improvements — confirmed reductions in waist circumference, blood lipids, blood pressure, serum uric acid, and liver enzymes across Phase 2 and Phase 3 data sets; over 1,500 subjects dosed across 17 clinical trialsCognitive function models — eBioMedicine/The Lancet (2025) confirmed Mazdutide significantly outperformed dulaglutide (a GLP-1 mono-agonist) in improving cognitive performance in db/db diabetic mice, with improvements in neuronal structure, brain tissue integrity, synaptic plasticity markers, and restoration of excitatory-inhibitory balance via VGluT2/NMDA/GABA pathwaysNeuroprotection research — GCGR activation shown to uniquely counteract glutamate excitotoxicity in diabetic cognitive dysfunction models — a pathway not addressed by GLP-1 mono-agonist comparators in the same studyHyperuricemia models — confirmed uric acid reduction in pre-clinical hyperuricemic rat models and across clinical trial populations; relevant for gout and metabolic syndrome researchAdolescent metabolic models — case report data confirmed Mazdutide produced 18.89% BMI reduction, 37% uric acid reduction, and 21.88% HbA1c reduction over 36 weeks in an adolescent model with obesity, T2DM, and hyperuricemiaMAFLD and MASH models — GCGR activation directly targets hepatic lipid metabolism pathways central to metabolic-associated fatty liver disease; Phase 3 liver fat data positions Mazdutide as a particularly relevant research tool for MAFLD and MASH studiesPre-clinical obesity models — confirmed robust dose-dependent bodyweight reduction and improved glucose tolerance across multiple DIO and db/db mouse model studiesWhat Do Studies Say About Mazdutide?Mazdutide has an exceptionally well-developed and rapidly growing clinical research literature:Ji L et al. (2025) — New England Journal of Medicine — GLORY-1 Phase 3 publication. Once-weekly Mazdutide in Chinese adults with obesity or overweight (610 participants, 48 weeks). Primary endpoints and all key secondary endpoints met. DOI: 10.1056/NEJMoa2411528Zhang B et al. (2024) — Diabetes Care, 47: 160–168 — Phase 2 randomised, double-blind, placebo-controlled trial confirming efficacy and safety of Mazdutide in Chinese patients with type 2 diabetes. Demonstrated significant HbA1c reduction and bodyweight loss with a well-tolerated safety profile. DOI: 10.2337/dc23-1287Ji L et al. (2023) — Nature Communications, 14: 8289 — Phase 2 randomised controlled trial of Mazdutide in Chinese overweight adults or adults with obesity. Confirmed significant bodyweight reduction (–11.3% vs –1% placebo), with improvements across multiple cardiometabolic markers. DOI: 10.1038/s41467-023-44067-4eBioMedicine / The Lancet (2025) — PMC12205698 — Pre-clinical multi-omics study demonstrating Mazdutide significantly outperformed dulaglutide on cognitive performance in db/db T2DM mice. Confirmed neuroprotection via GCGR-mediated counteraction of glutamate excitotoxicity, upregulation of BDNF, cAMP/PKA and PI3K–Akt activation, and restoration of synaptic excitatory-inhibitory balance — pathways not accessible via GLP-1 mono-agonism. DOI: 10.1016/S2352-3964(25)00235-XInnovent / ADA Scientific Sessions (2024) — GLORY-1 Phase 3 exploratory analysis presented at ADA 84th Scientific Sessions confirming 80.2% liver fat content reduction via MRI-PDFF in participants with baseline liver fat ≥5% — described by lead investigators as exceeding results from GLP-1 mono-agonists and other dual-target agonists in comparable studies.Front Endocrinol — Systematic Review & Meta-Analysis (2024) — DOI: 10.3389/fendo.2024.1309118 — Confirmed significant reductions in bodyweight and cardiometabolic parameters across pooled Mazdutide RCT data in both diabetic and non-diabetic populations.PMC Review (2025) — PMC12306892 / Drugs in Context — Confirmed Mazdutide as one of four dual GCGR-based agonists to complete Phase 2 trials and the only one with completed Phase 3 data (GLORY-1), with a second Phase 3 trial (GLORY-2) underway and three T2DM Phase 3 trials (DREAMS-1, DREAMS-2, DREAMS-3) ongoing. DREAMS-3 is a head-to-head comparison against semaglutide.Note: Phase 2 and Phase 3 clinical data relate to pharmaceutical development research. Mazdutide is not approved outside China (NDA under NMPA review as of 2025) and is not approved for medical or therapeutic use in the UK. All supply from Peptides Lab UK is for in-vitro and laboratory research use only.What is Mazdutide Used For in Research?Researchers purchasing Mazdutide from UK peptides suppliers like Peptides Lab UK typically investigate:Dual GLP-1R/GCGR receptor binding, activation, and co-agonism studiesObesity and metabolic syndrome pre-clinical and in-vitro modelsEnergy expenditure, fatty acid oxidation, and hepatic lipid metabolism researchType 2 diabetes and glycaemic control investigationLiver steatosis, MAFLD, and MASH model studiesHyperuricemia and uric acid metabolism researchCognitive function and diabetes-associated cognitive dysfunction (DACD) modelsNeuroprotection: glutamate excitotoxicity, synaptic plasticity, and BDNF pathway researchComparative dual agonist research alongside Survodutide, Pemvidutide, and RetatrutideDREAMS-3 trial-adjacent research: Mazdutide vs semaglutide comparative modelsStructure–activity relationship (SAR) studies within the oxyntomodulin analog classCardiometabolic comorbidity studies: blood pressure, dyslipidaemia, uric acidMazdutide vs Survodutide vs Semaglutide – Research ComparisonFeatureMazdutideSurvodutideSemaglutideReceptor TargetsGLP-1R GCGRGLP-1R GCGRGLP-1R onlyOriginOxyntomodulin analogGlucagon-derivedGLP-1 analogDeveloperInnovent / Eli LillyBoehringer Ingelheim / ZealandNovo NordiskPhase 3 DataYes (GLORY-1, NEJM 2025)Ongoing (SYNCHRONIZE)ApprovedBodyweight Reduction (Ph3)14.8% (6 mg, 48 wks)Ongoing~15% (2.4 mg, 68 wks)Liver Fat Reduction80.2% (MRI-PDFF, GLORY-1)Strong (GCGR)ModerateCognitive ResearchYes (eBioMedicine 2025)LimitedLimitedUric Acid ReductionYes (confirmed)Not primary focusNoRegulatory StatusNDA under NMPA reviewPhase 3Approved (UK, US, EU)Mazdutide’s 80.2% liver fat reduction and emerging cognitive research data are two unique differentiators that distinguish it from both Survodutide and approved semaglutide in the research literature.Quality & Purity AssuranceEvery batch of Mazdutide from Peptides Lab UK is:>99% pure — HPLC and mass spectrometry verifiedSupplied with a full Certificate of Analysis (COA) on requestLyophilised powder for maximum stability and long shelf lifeManufactured under strict, controlled laboratory conditionsConsistent batch-to-batch quality for reproducible research resultsWhy Buy Mazdutide from Peptides Lab UK?When you buy Mazdutide in the UK from Peptides Lab UK, you receive:99% purity, HPLC and MS verified, third-party testedFull COA documentation per batchFast same-day UK dispatch with tracked deliveryCompetitive pricing with bulk research discounts availableTrusted by researchers across the UK and EuropeResearch Disclaimer: All products supplied by Peptides Lab UK are intended strictly for in-vitro laboratory research and scientific study use only. They are not intended for human consumption, veterinary use, or any medical or therapeutic application. Mazdutide (IBI362) is an investigational compound currently under regulatory review in China and has not been approved by the MHRA, FDA, EMA, or any regulatory authority for human use outside of clinical trial settings. All clinical trial data and research citations on this page are published for scientific reference purposes and do not constitute a claim of safety or therapeutic efficacy for the research compound as supplied. Peptides Lab UK accepts no liability for any misuse of research compounds. By purchasing, you confirm that you are a qualified researcher and that the product will be used solely within a controlled laboratory environment in compliance with all applicable UK laws, regulations, and institutional guidelines.